AbbVie's Skyrizi sales growth raises investor worries about J&J competition
read at Endpoints ↗EarningsNegative
During AbbVie's first-quarter earnings call, analysts focused on the company's immunology franchise and asked how it would defend Skyrizi against emerging competition from Johnson & Johnson.
The call highlighted that Skyrizi continues to generate robust sales, yet investors expressed concern that a new J&J product could erode its market share.
AbbVie executives outlined a broad defense strategy but did not disclose specific plans or timelines for countering the anticipated competition.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AbbVie faces questions about Skyrizi competition from J&J”
read at Endpoints ↗84 words · retrieved Apr 29
comments(0)
5-min edit window · permanent after that